A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five ...

For patients with advanced renal cell carcinoma (RCC), there is a sustained clinical benefit with pembrolizumab plus axitinib ...

A study led by Roswell Park Comprehensive Cancer Center helps explain why a rare and hyper-aggressive subtype of kidney cancer is susceptible to immunotherapy—information that helped researchers ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Renal cell carcinoma (RCC) is often referred to as kidney cancer. It is estimated that 4,600 new cases of kidney cancer developed in Canada in 2009 and 1,600 people died from the disease (7).

Promising advanced kidney cancer pipeline therapies such as JANX008, IPI-549, Belzutifan, XmAbA 808, XL092, VB10.NEO, Savolitinib, RC198, NKT2152, NGM707, MEDI5752, ADI-270, ALLO 316, KO 2806, TT ...

During a live event, Sumanta K. Pal, MD, discussed lenvatinib dosing and tivozanib efficacy for patients with metastatic ...

The approval makes belzutifan the first agent indicated for renal cell carcinoma that has progressed after checkpoint inhibition and a VEGF-TKI. The oral hypoxia-inducible factor (HIF)-2 alpha ...

BOSTON — AVEO Oncology (Nasdaq: AVEO) today announced that the U.S. Food and Drug Administration (FDA) has approved FOTIVDA ® (tivozanib) for the treatment of adults with relapsed or refractory ...

Key Takeaways Welireg significantly improved quality-adjusted survival time over Afinitor in advanced renal cell carcinoma, with a mean Q-TWiST of 17.47 months versus 14.81 months. The relative gain ...